Merck has reported that the Chinese Phase III TAILOR study has demonstrated positive results of Erbitux (cetuximab) plus Folfox chemotherapy, compared with Folfox alone in patients with RAS wild-type metastatic colorectal cancer (mCRC). The ... Drug Development Technology, 1 month ago
BRIEF-Merck KGaA publishes Chinese Phase III study for Erbitux - Reuters UK, 1 month ago
Adding Merck KGaA's Erbitux to chemo helps to fight bowel cancer - Pharma Letter, 1 month ago
1 images for "erbitux"
Request Sample Report @ The Europe Erbitux Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Erbitux Industry. The report provides a basic overview of the industry including definitions, ...MyNewsDesk, 3 weeks ago Gastric Cancer Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 Press Release Ping, 2 weeks ago Oncology/Cancer Drugs Market 2016-2020: Global Industry Growth, Analysis and Report Forecast Digital Journal, 3 weeks ago GLOBAL & USA CANCER IMMUNOTHERAPY MARKET ANALYSIS TO 2020: Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors MyNewsDesk, 3 weeks ago
Adding cetuximab (Erbitux) to induction chemotherapy and hyperfractionated or accelerated chemoradiation therapy (CRT) produced long-term control for patients with HPV-negative, locoregionally advanced head and neck squamous cell carcinoma ...Targeted Oncology, 1 month ago
2016 Update of Biosimilar & Biosuperior Therapeutic Antibodies - Competitor Analysis: MarketResearchReports.Biz
MarketResearchReports.Biz has announced addition of new report Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update to its database. This press release was orginally distributed by SBWire Albany, NY -- (SBWIRE) -- ...Digital Journal, 1 day ago Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update Global Information Inc, 5 days ago
Source: ThinkstockThe rally that took place this week has been great, and the reasons from strategists are many, but one thing is for sure: things could get a little more dicey this summer. The first consideration of course is whether the Federal ...24/7 Wall St, 4 days ago
What's Really Driving Bristol-Myers Squibb's Valuation? ( Continued from Prior Part ) The Oncology segment With strong performance of Opdivo, Bristol-Myers Squibb's (BMY) Oncology segment has emerged as the largest revenue contributor for the ...Yahoo! Finance UK and Ireland, 4 days ago Behind Bristol-Myers Squibb's Continued Growth in 1Q16 Yahoo! 7 Finance, 5 days ago
ORIGINAL ARTICLE Ahead of print publication Qing Yang 1 , Zi-Lian Cui 2 , Qin Wang 3 , Xun-Bo Jin 4 , Yong Zhao 4 , Mu-Wen Wang 4 , Wei Song 4 , Hua-Wei Qu 4 , Wei-Ting Kang 4 1 Department of Breast and Thyroid Surgery, Shandong Provincial ...Asian Journal of Andrology, 4 days ago
By Laurie McGinley People with cancer that starts on the left side of their colon live significantly longer than those with right-side tumors, according to a new study that provides insights into how best to match drugs to patients with advanced ...Colorectal Cancer Association of Canada, 5 days ago Colon cancer patients survive longer when their tumors start on the left side Washington Post, 1 week ago
Source: Wikimedia CommonsNeedless to say, the health care sector, especially pharmaceuticals and biotech, have taken a rhetorical beating from politicians looking to force the blame for high drug prices on some of the top companies. While prices on ...24/7 Wall St, 6 days ago
This list includes more than 200 cancer drug information summaries from NCI . The summaries provide consumer-friendly information about cancer drugs and drug combinations. Summaries for individual cancer drugs cover the uses of these drugs, ...Arabstoday.net, 6 days ago
on your WebpageAdd Widget >Get your members hooked!